31 results about "Streptococcus pneumoniae bacteria" patented technology

The invention discloses a primer group for detecting respiratory tract microorganisms based on a nanopore sequencing method. The nucleotide sequences of the primer group are as shown in SEQ ID NO:1-20. The microorganisms are streptococcus pneumoniae, staphylococcus aureus (resisting to methicillin), klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, stenotrophomonas maltophilia, candida albicans, haemophilus influenzae, legionella pneumophila, enterococcus faecium, chlamydia psittaci, cryptococcus gattii, aspergillus fumigatus and pneumocystis jiroveci. According to the invention, sequencing optimization is carried out on different types of samples of the respiratory tract microorganisms, so that the detection method, the kit and the like are suitable for various typesof respiratory tract samples; and a targeted amplification method is adopted, so that the detection requirements of sputum, alveolar lavage and other sample types can be met. In addition, parallel sequencing can be performed, so that the flux of the detected samples is increased, the sequencing time is shortened, and the contradiction between the flux of detected pathogenic species and the cost and time is further relieved.

The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and / or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

The invention relates to a 15-valence pneumococcus conjugate combined vaccine. The combination particularly contains 2-type and 12 F serotypes, has a wide immunization coverage rate and is used for preventing infectious diseases caused by pneumococcus. The combined vaccine further contains a 1-type serotype, a 3-type serotype, a 4-type serotype, a 5-type serotype, a 6A serotype, a 6B serotype, a 7F serotype, a 9V serotype, a 14-type serotype, a 18 C serotype, a 19 A serotype, a 19 F serotype and a 23 F serotype.

This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides, antibodies thereto, and nucleic acids. Assays for compounds which modulate the polypeptides of the present invention for use in therapy are also provided.

The present invention relates to immunogenic compositions comprising 26 μg-45 μg of pneumolysin and / or PhtD, vaccines comprising the immunogenic compositions and their use in medicine.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

The invention is directed to multivalent pneumococcal glycoconjugate compositions containing a newly emerging serotype of S. pneumonia, polysaccharide 24F, and their manufacture and use. The pneumococcal serotype 24F contains a polysaccharide repeating unit structure. The multivalent immunogenic composition comprises at least 25 S. pneumonia capsular polysaccharides selected from the serotypes 1, 2, 3, 4, 5, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20, 22F, 23B, 23F, 24F, 33F and 35B of S. pneumoniae preferably conjugated to carrier protein either directly or through a linker and a pharmaceutically acceptable carrier and / or adjuvant. The disclosure provides the capsular polysaccharide structure of serotype 24F to understand the polysaccharide before conjugation with carrier protein.

The present invention relates to a multivalent Pneumococcal conjugate vaccine (PCV) composition comprising: 1) at least 12 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F of S. pneumoniae activated with CDAP and conjugated to carrier protein selected from CRM197, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA) or combination thereof and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharide from serotype 6A.

The present invention provides a process improvement related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae (S. pneumoniae) serotype 35B to a carrier protein. The serotype 35B polysaccharide-protein conjugate, prepared by the disclosed process, is, among other things, more immunogenic than similar conjugates made by prior art methods. S. pneumoniae serotype 35B polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccine compositions.

The invention discloses a rapid-recognition gene chip for pathogenic bacteria of pneumonia. The gene chip can detect 15 pathogenic bacteria including streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, mycoplasma pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, enterococcus faecalis, enterococcus faecium, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, stenotrophomonas maltophilia, burkholderia cepacia, legionella pneumophila and chlamydia pneumoniae, and clinically common and difficult-to-culture pathogenic bacteria are contained. In a preparation process of the gene chip, design, screening and verification of probes are performed by adopting 16S rDNA and a specific gene sequence corresponding to each of the pathogenic bacteria, and types of the bacteria in a to-be-detected sample are identified from levels of genus and species simultaneously and respectively. The gene chip has the advantages that the defect that clinical detection of the pathogenic bacteria of pneumonia is not timely and comprehensive at present is overcome, and one novel detection way is provided for early diagnosis and early treatment of patients with pneumonia.

The present invention provides an erythromycin derivative, characterized in that the erythromycin derivative comprises a compound of general formula I, or, the erythromycin derivative comprises a compound of general formula I and an inorganic acid or a pharmaceutically acceptable salt formed from an organic acid, the erythromycin derivatives can be better adapted to industrial production, and can be used against common erythromycin-resistant Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes Pathogenic bacteria such as cocci, Mora catarrhalis and Haemophilus influenzae have good anti-susceptible and anti-drug-resistant bacteria activities, and can effectively treat clinical bacterial pneumonia or other microorganisms (such as mycoplasma, Legionella, etc.) Pneumonia, and other tissue infections;

Provided are a method and a kit for accurately and rapidly detecting ten types of targeting pneumonia bacteria: Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, Klebsiella pneumoniae, Pseudomonas aeruginosa, Moraxella catarrhalis, methicillin-resistant Staphylococcus aureus (MRSA), and Staphylococcus aureus. A set of primer pairs directed to their respective target regions contained in the DnaJ gene, etc., of the ten types of pneumonia causative bacteria is designed for the ten bacterial strains and used to amplify gene products. A set of bacterial strain-specific probe pairs is further designed for the ten bacterial strains such that the probe pairs hybridize with the amplification products via sequences in the respective target regions differing from the sequences hybridized by the set of primer pairs. A first probe-bound labeled high molecular carrier in which plural types of first probes for the pneumonia bacteria are bound to a labeled high molecular carrier and a solid-phase second probe-carrying developing support are used as the set of probe pairs to perform nucleic acid chromatography.

The invention relates to a method of assessing whether a test compound is useful for alleviating a pneumococcal infection in an animal. This method comprises comparing (a) the degree of phosphorylation of CpsD in pneumococcal cells maintained in the presence of the test compound and (b) the degree of phosphorylation of CpsD in the same type of cells maintained in the absence of the test compound.

The invention relates to a special diluent for detecting Streptococcus pneumoniae in urine samples. The diluent is composed of five components: borax, 1307Prill, ε-polylysine, C-reactive protein polyclonal antibody, and purified water. The content of each component is as follows: borax as component I content is 50mM ~ 100mM, 1307Prill as component II content is 0.5% ~ 1%, ε‑polylysine as component III content is 0.5% ~ 1%, C‑reaction The content of protein polyclonal antibody as component IV is 10ug / ml-20ug / ml, and the rest is purified water. The diluent mixed with the urine sample at a volume ratio of 1:9 can effectively inhibit the interference of the C-reactive protein in the urine sample on the detection results of Streptococcus pneumoniae, significantly improve the detection rate of Streptococcus pneumoniae, and play an important role in the accurate detection of urine Streptococcus pneumoniae in fluid samples is of great significance and has good clinical application value.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The invention discloses a novel human antimicrobial peptide LL-37 derivative and its application. The amino acid sequence of the human antimicrobial peptide LL-37 derivative is shown in SEQ ID NO:1. The present invention also includes the application of the above-mentioned novel human antimicrobial peptide LL-37 derivative in the preparation of antibacterial drugs. The antibacterial drug is an antibacterial drug or an antifungal drug, and the bacteria or fungi are at least cryptococcus, histoplasma capsulata, Candida albicans, Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli and Salmonella A sort of. Compared with the prior art, the human antimicrobial peptide LL-37 derivative of the sequence of the present invention has the advantages of strong stability and good antibacterial effect, and has broad application prospects in the field of antibacterial drug preparation.

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, and the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing the protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and / or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The invention discloses a human Streptococcus pneumoniae surface protein monoclonal antibody and an antigen capture ELISA kit. The human Streptococcus pneumoniae surface protein monoclonal antibody is secreted and produced by a hybridoma cell line with the preservation number CCTCC No: C2017211. The human Streptococcus pneumoniae surface protein monoclonal antibody can be used to detect the human Streptococcus pneumoniae. The invention also discloses a human Streptococcus pneumoniae surface protein capture ELISA kit based on the monoclonal antibody.

Cold spot genes of S. pneumoniae are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the S. pneumoniae cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of S. pneumoniae, thus providing an improvement over currently available S. pneumoniae vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of S. pneumonia.

The objective of the present invention is to provide: an immunogenic composition comprising a Streptococcus pneumoniae polysaccharides-proteins conjugate, which comprises any one or more capsular polysaccharides selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F, which are derived from Streptococcuspneumoniae, and one or more carrier proteins conjugated to each of the capsular polysaccharides; and a preparation method therefor. According to one embodiment of the present invention, provided is an immunogenic composition for preventing or treating a pneumococcal infection.